Evidence map›Paper›PMID 34699540›Full record

ArticlePloS one2021

Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms.

Justin Sinclair, Laura Collett, Jason Abbott, David W Pate, Jerome Sarris, Mike Armour

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. A Scoping Systematic Review of Cannabis Use in Endometriosis.The Australian & New Zealand journal of obstetrics & gynaecology · 2026
    Article
  3. Review
  4. Endometriosis: An Immunologist's Perspective.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Optimization and Evaluation ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. ΔCardiovascular toxicology · 2023
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Justin SinclairNICM Health Research Institute, Western Sydney University, Sydney, NSW, Australia.ORCID 0000-0001-9960-3191
Laura CollettBristol Trials Centre, University of Bristol, Bristol, United Kingdom.
Jason AbbottSchool of Women's and Children's Health, UNSW, Sydney, NSW, Australia.
David W PateNICM Health Research Institute, Western Sydney University, Sydney, NSW, Australia.
Jerome SarrisNICM Health Research Institute, Western Sydney University, Sydney, NSW, Australia.ORCID 0000-0001-9287-8854
Mike ArmourNICM Health Research Institute, Western Sydney University, Sydney, NSW, Australia.ORCID 0000-0001-7539-9851
Western Sydney University · AUThe University of Melbourne · AUTranslational Research Institute · AUUniversity of Bristol · GBUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of cannabis for symptoms of endometriosis was investigated utilising retrospective archival data from Strainprint Technologies Ltd., a Canadian data technology company with a mobile phone application that tracks a range of data including dose, mode of administration, chemovar and their effects on various self-reported outcomes, including pelvic pain.

methodsA retrospective, electronic record-based cohort study of StrainprintTM users with self-reported endometriosis was conducted. Self-rated cannabis efficacy, defined as a function of initial and final symptom ratings, was investigated across the included symptom clusters of cramps, pelvic pain, gastrointestinal pain, nausea, depression, and low libido. Cannabis dosage form, dose and cannabinoid ratio information was also recorded.

resultsA total number of 252 participants identifying as suffering endometriosis recorded 16193 sessions using cannabis between April 2017 and February 2020. The most common method of ingestion was inhalation (n = 10914, 67.4%), with pain as the most common reported symptom being treated by cannabis (n = 9281, 57.3%). Gastrointestinal symptoms, though a less common reason for cannabis usage (15.2%), had the greatest self-reported improvement after use. Inhaled forms had higher efficacy for pain, while oral forms were superior for mood and gastrointestinal symptoms. Dosage varied across ingestion methods, with a median dose of 9 inhalations (IQR 5 to 11) for inhaled dosage forms and 1 mg/mL (IQR 0.5 to 2) for other ingested dosage forms. The ratio of THC to CBD had a statistically significant, yet clinically small, differential effect on efficacy, depending on method of ingestion.

conclusionsCannabis appears to be effective for pelvic pain, gastrointestinal issues and mood, with effectiveness differing based on method of ingestion. The greater propensity for use of an inhaled dosage delivery may be due to the rapid onset of pain-relieving effects versus the slower onset of oral products. Oral forms appeared to be superior compared to inhaled forms in the less commonly reported mood or gastrointestinal categories. Clinical trials investigating the tolerability and effectiveness of cannabis for endometriosis pain and associated symptoms are urgently required.

Indexed as

Administration, OralAdultAnalgesicsEndometriosisFemaleHumansMedical MarijuanaPain MeasurementPelvic PainRetrospective StudiesTreatment OutcomeAnalgesicsMedical Marijuana

Identifiers

PMID34699540
PMCPMC8547625
OpenAlexW3182583282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.